Mediwound (NASDAQ:MDWD) Receives Buy Rating from Oppenheimer

Mediwound (NASDAQ:MDWD)‘s stock had its “buy” rating restated by equities research analysts at Oppenheimer in a research report issued to clients and investors on Tuesday, AnalystRatings.com reports. They presently have a $7.00 target price on the biopharmaceutical company’s stock. Oppenheimer’s price target points to a potential upside of 161.19% from the stock’s previous close.

MDWD has been the subject of a number of other reports. Zacks Investment Research raised Mediwound from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Saturday, June 20th. HC Wainwright reissued a “buy” rating and set a $5.50 price target on shares of Mediwound in a research note on Thursday, May 21st.

NASDAQ:MDWD opened at $2.68 on Tuesday. The company has a current ratio of 3.08, a quick ratio of 2.89 and a debt-to-equity ratio of 0.15. Mediwound has a 12-month low of $1.44 and a 12-month high of $4.14. The stock has a 50-day moving average price of $2.15 and a 200 day moving average price of $2.42. The stock has a market capitalization of $72.90 million, a P/E ratio of 11.17 and a beta of 1.41.

Mediwound (NASDAQ:MDWD) last released its earnings results on Wednesday, May 20th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.05. Mediwound had a negative return on equity of 75.91% and a net margin of 18.46%. The firm had revenue of $4.44 million during the quarter, compared to analysts’ expectations of $4.25 million. On average, research analysts predict that Mediwound will post -0.41 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in shares of Mediwound by 42.0% in the 4th quarter. Renaissance Technologies LLC now owns 407,408 shares of the biopharmaceutical company’s stock valued at $1,263,000 after purchasing an additional 120,508 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Mediwound by 136.4% in the 1st quarter. Acadian Asset Management LLC now owns 130,072 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 75,045 shares during the last quarter. Fortis Advisors LLC bought a new stake in shares of Mediwound in the 1st quarter valued at approximately $108,000. UBS Group AG lifted its stake in shares of Mediwound by 203.3% during the 4th quarter. UBS Group AG now owns 9,566 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 6,412 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Mediwound by 547.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,968 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 7,583 shares during the last quarter. 22.86% of the stock is owned by institutional investors and hedge funds.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Further Reading: What is the QQQ ETF?

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.